# Carbocisteine for COPD Exacerbation: Meta-Analysis & Safety
> Explore a systematic review and meta-analysis on Carbocisteine (1500 mg/day) effectiveness in reducing COPD exacerbation rates based on global RCT evidence.

Tags: copd, carbocisteine, systematic-review, meta-analysis, pulmonology, respiratory-health, medical-research, rct
## Carbocisteine in COPD Management: A Systematic Review and Meta-Analysis
- Focuses on evidence from Randomized Controlled Trials (RCTs) regarding exacerbation reduction and safety.
- Source reference: Advances in Respiratory Medicine 2026, 94, 2.

## Background & Rationale
- COPD is characterized by excessive mucus and airway obstruction.
- Acute exacerbations drive morbidity and mortality.
- Carbocisteine (1500 mg/day) acts as a mucoactive, antioxidant, and anti-inflammatory agent.

## Materials & Methods
- Databases searched: PubMed, Embase, Cochrane Library, and ClinicalTrials.gov.
- Inclusion criteria: Randomized, double-blind, placebo-controlled trials; Patients with FEV1/FVC < 0.70; Minimum 6 months follow-up.
- Analysis: Weighted Mean Difference (WMD) for exacerbations and Odds Ratio (OR) for adverse events.

## Study Selection & Included Trials
- 65 records identified; 4 studies met all criteria (Total n = 1,746 patients).
- Included studies: Allegra et al. (1996), Yasuda et al. (2006), Zheng et al. (2008), Zhou et al. (2025).
- All trials rated as low risk of bias according to Cochrane RoB2 tool.

## Meta-Analysis Results: Exacerbation Rates
- Overall WMD: -0.40 (95% CI: -0.69 to -0.11).
- Finding: Carbocisteine significantly reduces the annual COPD exacerbation rate compared to placebo.
- High heterogeneity noted (I² = 90%).

## Safety Profile: Adverse Events Analysis
- Pooled Odds Ratio (OR): 1.02 (95% CI: 0.76–1.37).
- Result: No significant difference in adverse events between Carbocisteine and placebo.
- Reported events: Gastrointestinal (dyspepsia, nausea) and Respiratory (sore throat, cough).
- Conclusion: Carbocisteine is well-tolerated with no hepatotoxicity or cardiovascular complications identified.
---
This presentation was created with [Bobr AI](https://bobr.ai) — an AI presentation generator.